Alembic Pharmaceuticals Incorporates Wholly Owned Subsidiary in Germany
Alembic Pharmaceuticals Ltd has established a new foreign venture by incorporating a wholly owned subsidiary in Germany. The subsidiary, named Alembic Pharmaceuticals GmbH, marks the company's strategic move to expand its reach and business operations in the German market.The establishment of Alembic Pharmaceuticals GmbH is aimed at exploring new business opportunities within the geography. This expansion will facilitate the promotion, sale, and distribution of the company's pharmaceutical products.
The new subsidiary operates in the pharmaceuticals industry. Financial details confirm that Alembic Pharmaceuticals GmbH has a registered share capital of EUR 25,000 (Euros Twenty Five Thousand Only), divided into 25,000 shares, with each share valued at EUR 1.00.
The company's investment represents 100% control over Alembic Pharmaceuticals GmbH.
The subsidiary is newly incorporated and is yet to commence business operations, with its current turnover reported as Nil.
Key details regarding the subsidiary’s structure and ownership are provided below:
| Detail | Description |
|---|---|
| Subsidiary Name | Alembic Pharmaceuticals GmbH |
| Location | Germany |
| Industry | Pharmaceuticals |
| Share Capital | EUR 25,000 (Euros Twenty Five Thousand Only) |
| Shares | 25,000 shares of EUR 1.00 each |
| Ownership Stake | 100% held by Alembic Pharmaceuticals Ltd |
| Current Turnover | Nil (yet to commence business operations) |
APLLTD Stock Price Movement
Shares of Alembic Pharmaceuticals Limited are rallying to ₹773.2 as of 1:18 PM, marking an upward swing of 1.12% in live trading. The equity finds fresh momentum supported by brisk activity, with 36,277 shares traded so far today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.